MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-18-0000781
Megafine Pharma Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹310.01 Cr
▼ 5% YoY
Net profit · FY 2025
₹29.08 Cr
Net margin 9.4%
EBITDA · FY 2025
₹50.29 Cr
EBITDA margin 16.2%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹1.53 Cr
Issued & subscribed
Open charges
₹48 Cr
Satisfied ₹48.75 Cr
Company age
31 yrs
Est. 1995
Employees · EPFO
758
Provident fund records
About Megafine Pharma Private Limited
Data last updated:
Megafine Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 22 August 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1995PTC092028. Its GSTIN is 27AAACM7472M1ZZ (Maharashtra). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.53 Cr. It is led by directors including Shailesh Jethmal Sanghvi (Managing Director) and Rohit Brijmohan Mantri.
Its last annual general meeting (AGM) was held on 17 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹310.01 Cr, a decline of 5% compared to the previous year. For the same year it recorded a net profit of ₹29.08 Cr (net margin 9.4%) and EBITDA of ₹50.29 Cr (EBITDA margin 16.2%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 11% over five years.
The company has about 758 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Megafine. As per MCA filings, the company has open charges of ₹48 Cr and satisfied charges of ₹48.75 Cr on record. Court records list 23 cases involving the company, including 7 filed by the company and 17 filed against it; 3 cases are pending. The company has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025. Its 10 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Valiant Laboratories Limited with revenue of ₹338.77 Cr. The company has 10 MSME Form 1 returns on record between 2019 and 2024, listing 152 overdue payments to 32 micro and small suppliers.
Megafine Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0000781). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website megafine.in.
Company details
CIN U24239MH1995PTC092028
Registration Number 092028
Incorporation Date 22 August 1995
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 17 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-18-0000781
Key People
Shailesh Jethmal Sanghvi Managing Director Rohit Brijmohan Mantri Nominee Director Hari Prasshanth Nominee Director Recognitions & Rankings of Megafine Pharma
Contact details
Megafine Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is megafine.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address901 A Wing Naman Midtown, Senapati Bapat Marg Prabhadevi, Mumbai, Maharashtra, India – 400013
- IndustryPharma, API Manufacturers
To see the full contact details of Megafine Pharma Private Limited, buy the company report.
Comprehensive company report
Megafine Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Megafine Pharma operates one associated brand: Megafine. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Company manufacturing its own Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates, and also offering CDMO services for innovator and generic pharma companies | megafine.in |
Business activity
The main business activity of Megafine Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Megafine Pharma Private Limited, buy the company report.
Financials of Megafine Pharma Private Limited
FY 2025 filings availableMegafine Pharma Private Limited reported revenue of ₹310.01 Cr (down 5% YoY) for FY 2025.
Revenue · FY 2025
₹310.01 Cr ▼ 5%
Net profit · FY 2025
₹29.08 Cr margin 9.4%
EBITDA · FY 2025
₹50.29 Cr margin 16.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 5%
3 years · compounded
▲ 7%
5 years · compounded
▲ 11%
EBITDA CAGR growth
1 year
▼ 13%
3 years · compounded
▲ 5%
5 years · compounded
▲ 69%
Revenue fell 5% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 11%. EBITDA fell 13% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹50.29 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹29.08 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.2% | ||||
| Net Profit Margin | 9.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Megafine Pharma Private Limited, buy the company report.
Board of directors of Megafine Pharma Private Limited
Megafine Pharma has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rohit Brijmohan Mantri Also directs: India Realty Excellence Fund II LLP, Symbiotec Biologics Private Limited, Symbiotec Zenfold Private Limited and 5 more | Nominee Director | 21 Feb 2025 | 1 Years 8 Months | Current |
| Shailesh Jethmal Sanghvi Also directs: Aar Cube Enterprise LLP, JMS Venture LLP | Managing Director | 22 Aug 1995 | 31 Years 2 Months | Current |
| Hari Prasshanth | Nominee Director | 06 Mar 2025 | 1 Years 7 Months | Current |
Peer comparison
Megafine Pharma Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Valiant Laboratories Limited | ₹338.77 Cr (FY 2023) | 61.0% | Mumbai, Maharashtra, India | |||
| Mehta Api Private Limited | ₹325.77 Cr (FY 2025) | 36.0% | Mumbai, Maharashtra, India | |||
| Synergene Active Ingredients Private Limited | ₹319.93 Cr (FY 2024) | 37.0% | Hyderabad, Telangana, India | |||
| Mangalam Drugs and Organics Limited | ₹318.73 Cr (FY 2025) | -14.0% | Mumbai, Maharashtra, India | |||
| Saraca Laboratories Limited | ₹310.45 Cr (FY 2025) | 11.0% | Hyderabad, Telangana, India | |||
| Megafine Pharma Private Limitedthis company | ₹310.01 Cr (FY 2025) | ₹29.08 Cr | 9.4% | -5.0% | 758 | Mumbai, Maharashtra, India |
| Bal Pharma Limited | ₹305.29 Cr (FY 2025) | -11.0% | Bangalore, Karnataka, India | |||
| Optrix Laboratories Private Limited | ₹304.7 Cr (FY 2020) | 43.0% | Hyderabad, Telangana, India | |||
| Ajinomoto Bio-Pharma Services India Private Limited | ₹301.41 Cr (FY 2025) | 56.0% | Anakapalle, Andhra Pradesh, India | |||
| Alembic Limited | ₹296.78 Cr (FY 2025) | 40.0% | Vadodara, Gujarat, India | |||
| Anjan Drug Private Limited | ₹293.42 Cr (FY 2025) | -14.0% | Chengalpattu Dt, Tamil Nadu, India |
To see the full peer comparison of Megafine Pharma Private Limited, buy the company report.
Auditor
Megafine Pharma Private Limited is audited by Jain Ambavat & Associates LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Jain Ambavat & Associates LLP | FY 2024 | 103887W/W100364 |
Shareholding
The shareholding of Megafine Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Megafine Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹48 Cr
Satisfied charges
₹48.75 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Apr 2012 | 10350830 | Hdfc Bank Limited | ₹8.5 Cr | Open | |
| 13 Jun 2006 | 10007239 | State Bank of India | ₹39.5 Cr | Open | |
| 22 Nov 2019 | 100304683 | Hdfc Bank Limited | ₹44.5 Cr | Satisfied | |
| 29 Sep 2003 | 90160214 | Canara Bank | ₹2.7 Cr | Satisfied | |
| 05 Jun 2002 | 90160114 | Canara Bank | ₹8 Lakh | Satisfied |
To see the full charge records of Megafine Pharma Private Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Megafine Pharma Private Limited has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025.
Total deals
8
Secondary share transfers
6
Funding round
1
Acquisition
1
Disclosed funding
₹1.2 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2025 | Acquisition | ₹460 Cr | Buyer: Motilal Oswal Private Equity |
| Sep 2022 | Secondary share transfer | Undisclosed | Seller: 4 individuals |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2015 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Hasmukh P Gandhi HUF, Dharmesh P Gandhi HUF, Mukesh J Sanghvi HUF Seller: 4 individuals |
To see the full deal history of Megafine Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Megafine Pharma Private Limited has 23 court cases on record: 7 filed by Megafine Pharma, 17 filed against it. 3 cases are pending and 20 are disposed.
Total cases
23
Filed by the company
7
Filed against the company
17
Pending
3
Disposed
20
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 17 | 11 | 2 |
| District courts | 6 | 6 | 1 |
Cases on record (5 of 23)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Company petition | Filed against the company by Mega Fine Pharma Pvt.Ltd. | Disposed |
| Bombay High Court | Appeal | Filed by the company against Super Fine Laboratories Private Ltd.With Mega Fine Pharma P.Ltd. and 1 other | Disposed |
| Bombay High Court | Company petition | Filed by the company against Super Fine Laboratories Pltd.And Mega Fine Pharma P.Ltd. and 1 other | Disposed |
| Bombay High Court | Tax appeal | Filed against the company by PR Commissioner of Income Tax 4 | Pending |
| High Court, GUJARAT | Special civil application | Filed by the company against State of Gujarat and 2 others | Pending |
To see the full case history of Megafine Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Megafine Pharma Private Limited was last rated by Care on 05 Dec 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 05 Dec 2022 |
To see the full credit ratings and regulatory alerts of Megafine Pharma Private Limited, buy the company report.
MSME payment delays
Megafine Pharma Private Limited has 10 MSME Form 1 returns on record between 2019 and 2024, listing 152 overdue payments to 32 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 32)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| Jai Lakshmi Agro Chemicals Private Limited | |||
| Bombay Ammonia & Chemical Company | |||
| an individual supplier |
To see the full MSME payment records of Megafine Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Megafine Pharma Private Limited has a workforce of 758 employees on its EPFO records as of Dec 12, 2024, across 2 active EPFO establishments.
Employee count
758
Active EPFO establishments
2
Employee growth
0.4%
GST
Megafine Pharma has 3 GST registrations: 2 active and 1 cancelled or inactive.
Total GSTINs
3
Active
2
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACM7472M1ZZ | Maharashtra | Active | 01 Jul 2017 |
| 24AAACM7472M1Z5 | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Megafine Pharma Private Limited, buy the company report.
Recent activity
Megafine Pharma Private Limited has 6 board changes on record since 1995: 3 appointments and 3 cessations. The latest: Hari Prasshanth was appointed as Nominee Director on 06 Mar 2025.
AGM
Megafine Pharma Private Limited last Annual general meeting of members was held on 17 Sep 2025 as per latest MCA records.
Filing
Megafine Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Appointed
Hari Prasshanth was appointed as Nominee Director.
Appointed
Rohit Brijmohan Mantri was appointed as Nominee Director.
Charges
A charge registered on 22 Nov 2019 via Charge ID 100304683 with Hdfc Bank Limited was fully satisfied on 14 Aug 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 8.50 Cr registered on 26 Apr 2012 with Charge ID 10350830 was modified on 01 Aug 2024.
Charges
A charge with State Bank Of India of Rs. 39.50 Cr registered on 13 Jun 2006 with Charge ID 10007239 was modified on 20 Jul 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 44.50 Cr with Charge ID 100304683 was registered on 22 Nov 2019.
Ceased
Kunal Ashok Jhaveri ceased to be Additional Director.
Ceased
Ashok Kirtilal Jhaveri ceased to be Whole-Time Director.
Ceased
Hasmukh Purushottam Gandhi ceased to be Director.
Charges
A charge registered on 05 Jun 2002 via Charge ID 90160114 with Canara Bank was fully satisfied on 06 Jun 2012.
16 earlier events are in the company report.
News
Frequently asked questions
Megafine Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 22 August 1995 (31+ years old) and is registered under CIN U24239MH1995PTC092028.
Megafine Pharma has 3 current directors:
- Shailesh Jethmal Sanghvi - Managing Director
- Rohit Brijmohan Mantri - Nominee Director
- Hari Prasshanth - Nominee Director
The latest financial statements of Megafine Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 17 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Megafine Pharma is 27AAACM7472M1ZZ, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 24AAACM7472M1Z5 (Gujarat).
The CIN (Corporate Identification Number) of Megafine Pharma is U24239MH1995PTC092028. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Megafine Pharma has 23 court cases on record: 7 filed by the company and 17 filed against it. 3 are pending. Most are in the high courts.
Megafine Pharma was incorporated on 22 August 1995, making it 31+ years old. It is registered with the Registrar of Companies, Mumbai.
Megafine Pharma has 8 deals on record (6 secondary share transfers, 1 funding round, 1 acquisition), with disclosed funding of ₹1.2 Cr; the latest was in February 2025.
The peers of Megafine Pharma by revenue are Valiant Laboratories Limited, Mehta Api Private Limited, Synergene Active Ingredients Private Limited, Mangalam Drugs and Organics Limited, Saraca Laboratories Limited and 5 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Hari Prasshanth was appointed as Nominee Director on 06 Mar 2025. Rohit Brijmohan Mantri was appointed as Nominee Director on 21 Feb 2025. Kunal Ashok Jhaveri ceased to be Additional Director on 27 Sep 2019. Megafine Pharma has 6 board changes on record in total.
Yes, Megafine Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-18-0000781).
Megafine Pharma has 10 MSME Form 1 returns on record between 2019 and 2024, listing 152 overdue payments to 32 micro and small suppliers. The latest return was filed on 30 Apr 2024.